Adamantan-2-yl-ethyl-amine | 46176-57-2

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: Adamantan-2-yl-ethyl-amine
• 英文别名: N-ethyladamantan-2-amine
• CAS: 46176-57-2
• 化学式: C₁₂H₂₁N
• mdl: 36.4606
• 分子量: 179.305
• InChiKey: LBUOWFRNFOQBRE-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  3.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• Cannabinoid receptor ligands and uses thereof
  申请人：Pfizer Inc.

  公开号：US20040214837A1

  公开（公告）日：2004-10-28

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein. 1

  本文描述了作为大麻素受体配体的化合物（I）及其在治疗与动物体内大麻素受体介导相关疾病中的用途。
• [EN] NOVEL ADAMANTANE AND MEMANTINE DERIVATIVES AS PERIPHERAL NMDA RECEPTOR ANTAGONISTS<br/>[FR] NOUVEAUX DÉRIVÉS ADAMANTANE ET MÉMANTINE UTILISÉS COMME ANTAGONISTES PÉRIPHÉRIQUES DES RÉCEPTEUR NMDA
  申请人：INSERM (INSTITUT NAT DE LA SANTÉ ET DE LA RECH MÉDICALE)

  公开号：WO2017017116A1

  公开（公告）日：2017-02-02

  The present invention relates to cationic compounds of formula (I) for use as peripheral NMDA receptor antagonists.

  本发明涉及公式（I）的阳离子化合物，用作外周NMDA受体拮抗剂。
• 2-adamantylethylamines and their use in the treatment of conditions generally associated with abnormalities in glutamatergic transmission
  申请人：——

  公开号：US20030207881A1

  公开（公告）日：2003-11-06

  The use of a compound of formula (I): wherein R 1 , R 2 , R 3 , R 4 , R 5 and R 6 are independently selected from hydrogen, alkyl, aryl and non-aromatic heterocyclic groups, or each of one or more pair(s) of the substituent groups R 1 to R 6 may together form a 3, 4, 5, 6, 7 or 8-membered ring containing 0, 1 or 2 heteroatom(s); R 7 is selected from alkyl, aryl and non-aromatic heterocyclic groups, and R 8 is selected from hydrogen, halogen, alkyl, aryl and non-aromatic heterocyclic groups; and pharmaceutically acceptable salts and prodrugs thereof, in the manufacture of a medicament for use in the treatment of a condition generally associated with abnormalities in glutamatergic transmission; novel compounds of formula (1) per se and for use in therapy. 1

  本发明涉及使用化合物的公式（I）：其中R1、R2、R3、R4、R5和R6独立选择氢、烷基、芳基和非芳香杂环基团，或者其中一对或多对取代基R1到R6可以共同形成一个包含0、1或2个杂原子的3、4、5、6、7或8元环；R7选择烷基、芳基和非芳香杂环基团，R8选择氢、卤素、烷基、芳基和非芳香杂环基团；以及其药学上可接受的盐和前药，在制造用于治疗通常与谷氨酸能传递异常有关的疾病的药物中使用；本发明涉及公式（1）的新化合物本身及其在治疗中的使用。
• CANNABINOID RECEPTOR LIGANDS AND USES THEREOF
  申请人：Griffith A. David

  公开号：US20070275964A1

  公开（公告）日：2007-11-29

  Compounds of Formula (I) that act as cannabinoid receptor ligands and their uses in the treatment of diseases linked to the mediation of the cannabinoid receptors in animals are described herein.

  本文描述了化学式为(I)的化合物，它们作为大麻素受体配体并在动物中治疗与大麻素受体介导相关的疾病中的用途。
• Tetracycline Compounds
  申请人：Chen Chi-Li

  公开号：US20120135968A1

  公开（公告）日：2012-05-31

  The present invention is directed to a compound represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. The variables for Structural Formula I are defined herein. Also described is a pharmaceutical composition comprising the compound of Structural Formula I and its therapeutic use.

  本发明涉及一种由结构式(I)表示的化合物或其药学上可接受的盐。结构式I的变量在此定义。同时还描述了包含结构式I化合物的药物组合物及其治疗用途。